Mentioned in ?
References in periodicals archive ?
XAGRID, as anagrelide hydrochloride, was designated as an orphan medicinal
Anagrelide hydrochloride is marketed by Shire in the US and Canada under the trademark AGRYLIN(R) and will be marketed in Europe under the trademark XAGRID(R).
XAGRID, as anagrelide hydrochloride, was designated as an orphan medicinal product on 29 December 2000 for the treatment of ET, thereby providing the product with up to ten years market exclusivity in Europe from the date of grant of the license.
Anagrelide Hydrochloride capsules are approved for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
s Abbreviated New Drug Application for Anagrelide Hydrochloride Capsules, 0.
methylphenidate (METHYPATCHA'), anagrelide hydrochloride (XAGRIDA'),
Anagrelide hydrochloride is marketed by Shire in the US(1) and Canada under the trademark AGRYLIN(R) and will be marketed in Europe under the trademark XAGRID(R).
Anagrelide is already marketed in the US and Canada under the trademark AGRYLIN(TM), an oral formulation of anagrelide hydrochloride, licensed for the treatment of Essential Thrombocythemia (ET).
Drug Profiles discussed in this report are anagrelide hydrochloride CR, BMS-911543, buparlisib hydrochloride, CWP-291, erismodegib, evofosfamide, givinostat, glasdegib, Hu8F4, idelalisib, imetelstat sodium, INCB-39110, KB-004, LCL-161, momelotinib dihydrochloride, NS-018, pacritinib, pixantrone dimaleate, pomalidomide, PRM-151, rigosertib sodium, ropeginterferon ALFA-2B, simtuzumab, SL-401 and sotatercept.